Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 7/20 | 0.65 |
| ▸ | MAP2K7 | O14733 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | ITK | Q08881 | 2/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TGM1 | P22735 | 1/20 | 0.49 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TDP2 | O95551 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4103284 | 0.91 | TGM2 (0.76) | TGM2MAP2K7LPAR1LPAR2EGFR | |
| SCHEMBL6355891 | 0.86 | TGM2 (0.65) | TGM2LPAR1LPAR2EGFR | |
| SCHEMBL31536255 | 0.82 | TGM2 (0.65) | TGM2MAP2K7EGFRITK | |
| SCHEMBL1383747 | 0.82 | TGM2 (0.65) | TGM2MAP2K7EGFRITK | |
| SCHEMBL21469043 | 0.81 | TGM2 (0.59) | TGM2MAP2K7LPAR1LPAR2EGFR | |
| SCHEMBL22600366 | 0.81 | TGM2 (0.59) | TGM2MAP2K7LPAR1LPAR2EGFR | |
| SCHEMBL15693010 | 0.81 | TGM2 (0.71) | TGM2MAP2K7EGFRITKF13A1 | |
| SCHEMBL19501282 | 0.81 | TGM2 (0.76) | TGM2LPAR1LPAR2EGFRBTK | |
| SCHEMBL1925142 | 0.81 | KMT2A (0.71) | TGM2LMNA | |
| SCHEMBL20750046 | 0.80 | TGM2 (0.58) | TGM2MAP2K7LPAR1LPAR2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382900-A1 | INHIBITORS OF BTK | NEWAVE PHARMACEUTICAL INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-3553064-B1 | COMPOUND CONTAINING TRICYCLIC HETEROARYL GROUP | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2023-06-07 | — | — | EP | disclosed |
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | UNIVERSITY OF MASSACHUSETTS | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382900-A1 | INHIBITORS OF BTK | BTK, SYK, LYN | TGM2 2565/4885MAP2K7 1143/4885LPAR1 1980/4885 |
| US-20200339596-A1 | FUROXAN-BASED COMPOUNDS AND USES THEREOF | PARK7, HTT, PRDX5 | TGM2 2258/4885MAP2K7 4830/4885LPAR1 3099/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | TGM2 1889/4885MAP2K7 173/4885LPAR1 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.